Scilex Holding Company announced that it has responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison during review of a New Drug Submission to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB for acute treatment of migraine with or without aura in Canada. Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy and those who have contraindications to triptan use. ELYXYB’s product profile mapped with a high degree of certainty to these stated unmet needs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCLX:
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
- Scilex enters release, settlement agreement with Virpax Pharmaceuticals
- Riding the Biotech Rollercoaster: Scilex’s Stock Volatility Amid Sector Uncertainty
- Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering
